Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Development of carbohydrate based anticancer agents

Cel

CarboMed will assess the commercial viability of targeting cancer cell glycosylation as a next-generation therapeutic strategy to treat cancer in the clinic. Carbohydrates (glycans) coat the cell of every organism. The glycosylation pattern of cancer cells is, however, very different from that of healthy cells and is associated with aggressive and invasive forms of cancers. By combining our knowledge on carbohydrate chemistry and cancer immunology we targeted the cancer-cell protecting carbohydrate coat, hampering the cancer's ability to grow and metastasize. In this project, we aim to deliver a technical and commercial proof-of-concept for targeting the glycosylation of cancer cells to ultimately enable clinical studies

Instytucja przyjmująca

STICHTING RADBOUD UNIVERSITEIT
Wkład UE netto
€ 150 000,00
Adres
HOUTLAAN 4
6525 XZ Nijmegen
Niderlandy

Zobacz na mapie

Region
Oost-Nederland Gelderland Arnhem/Nijmegen
Rodzaj działalności
Higher or Secondary Education Establishments
Linki
Koszt całkowity
Brak danych

Beneficjenci (1)